Literature DB >> 8418185

Oral immunization with influenza virus in biodegradable microspheres.

Z Moldoveanu1, M Novak, W Q Huang, R M Gilley, J K Staas, D Schafer, R W Compans, J Mestecky.   

Abstract

Polymeric microspheres were evaluated as an oral antigen delivery system for immunization with influenza virus. The immune responses obtained were compared after either oral or systemic immunization of BALB/c mice using purified, formalin-inactivated influenza virus type A/H3N2, either encapsulated in biodegradable and biocompatible microspheres or free in solution. The immunogenicity of formalin-treated influenza vaccine was preserved during the microencapsulation process, and the microencapsulated antigen induced protective immune responses after systemic immunization that were equal to or higher than those induced by conventional vaccine. When administered orally to primed animals, microencapsulated antigen induced levels of anti-influenza antibodies in saliva that were higher than and in serum that were comparable to those obtained by systemic immunization. Furthermore, oral booster immunization provided virtually complete protection of animals challenged with live virus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418185     DOI: 10.1093/infdis/167.1.84

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.

Authors:  B Baras; M A Benoit; L Dupré; O Poulain-Godefroy; A M Schacht; A Capron; J Gillard; G Riveau
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.

Authors:  Milan Raska; Zina Moldoveanu; Jan Novak; Zdenek Hel; Lea Novak; Jadranka Bozja; Richard W Compans; Chinglai Yang; Jiri Mestecky
Journal:  Vaccine       Date:  2008-02-07       Impact factor: 3.641

Review 3.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates.

Authors:  S B Periwal; T J Speaker; J J Cebra
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 5.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

6.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.

Authors:  A Roberts; E Kretzschmar; A S Perkins; J Forman; R Price; L Buonocore; Y Kawaoka; J K Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  Oral vaccination with inactivated influenza vaccine induces cross-protective immunity.

Authors:  Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

Review 8.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection.

Authors:  R Ashley; A Wald; L Corey
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 10.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.